Short answer · Medically reviewed summary · Last updated: 2026-04-07
Factor V Leiden is an inherited genetic condition caused by a specific mutation in the F5 gene, which alters the Factor V protein and makes blood more prone to clotting. The Genetic Basis of Factor V Leiden The primary cause of Factor V Leiden is a single point mutation in the F5 gene located on chromosome 1. Think of the F5 gene as an instruction manual for building a protein that helps regulate blood clotting.
5 people with Factor V Leiden have shared their first-person experience on this question at DiseaseMaps.
Factor V Leiden is an inherited genetic condition caused by a specific mutation in the F5 gene, which alters the Factor V protein and makes blood more prone to clotting.
The primary cause of Factor V Leiden is a single point mutation in the F5 gene located on chromosome 1. Think of the F5 gene as an instruction manual for building a protein that helps regulate blood clotting. In individuals with this condition, a "typo" in the manual causes the body to produce a version of the Factor V protein that is resistant to being "turned off" by a natural anticoagulant called activated protein C. Because this protein remains active for too long, the blood remains in a hypercoagulable state, increasing the risk of thrombosis.
It is important to distinguish between the cause (the genetic mutation) and risk factors (conditions that trigger a clot). You can inherit Factor V Leiden from one parent (heterozygous) or both parents (homozygous). While the mutation is the underlying cause, environmental factors often act as catalysts. These include prolonged immobility, surgery, pregnancy, the use of oral contraceptives, or underlying inflammatory states. These factors don't cause the Factor V Leiden mutation itself, but they interact with the already "sticky" blood to make a clot more likely to form.
The etiology of Factor V Leiden is well-understood at the molecular level, though researchers are still studying why some individuals with the mutation never experience a clot while others do. Current clinical literature focuses on identifying secondary genetic modifiers—other genes that might interact with the F5 mutation to increase or decrease individual risk. Understanding these interactions is a major area of hematological research, as it helps physicians move toward personalized risk assessments rather than relying solely on the presence of the mutation.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.